Objectives: To determine the rate of self-reported adherence by pediatricians to the 1995 American Academy of Pediatrics and the Advisory Committee on Immunization Practices varicella immunization recommendations and to evaluate factors that might influence adherence.
, the Food and Drug Administration licensed live attenuated varicella vaccine for use in children 12 months of age and older. Both the American Academy of Pediatrics (AAP) and the Immunization Practices Advisory Committee (ACIP) of the Centers for Disease Control and Prevention have recommended universal varicella vaccination for children aged 12 months old and older who do not have a reliable history of varicella. 1, 2 In addition to reducing morbidity and mortality associated with varicella infection, universal varicella vaccination has been shown to be theoretically cost-effective, saving more than $5 at the societal level for each dollar spent on immunization. 3 This finding was based in part on a 1992 survey indicating that the mean value of the parental time lost from work was $183 for each case of varicella. 4 However,routineimmunizationagainst varicellahasnotbeenunanimouslyendorsed by the medical community. Numerous editorials and letters criticizing the implementation of universal varicella immunization havebeenpublished. [5] [6] [7] Ofconcernisthepossibility that immunization of preschool-aged childrenmayleadtovaricellabecomingadis-easeofolderchildrenandadults,withaconcomitantincrease in disease severity. 8 Theoretical models using varying rates of vaccine efficacy, waning immunity, and immunization predict that routine vaccination will result in an age shift in varicellacasestowardolderindividuals. 9 However,thesemodels also suggest that the overall morbidity from chickenpox will be reduced. 9 Another theoretical barrier to the acceptance of the varicella vaccine has been the lack of direct medical cost savings. Varicella infection is usually a medically benign event; it has been estimated that a major complication requiring hospitalization occurs only 1.5 times per 1000 cases of chickenpox among 5-to 9-year-old children. 3 Because complications are rare, the medical cost savings of a varicella immunization program are likely to be outweighed by the cost of the program itself, leading to an estimated cost of approximately $2 for every case of varicella prevented. The WVAC noted the lack of consensus with regard to the AAP and ACIP recommendation for universal varicella immunization of healthy children age 12 months to 12 years who lack a reliable history of varicella. The WVAC concluded that parents of children age 12 months to 12 years should discuss the risks of VZV [varicella zoster virus] infection and the benefits and risks of live attenuated varicella vaccine with their child's health care provider. If a decision to vaccinate is made, the vaccine should be available for these children.
PARTICIPANTS AND METHODS
A 4-page questionnaire, personalized cover letter, and a return envelope were mailed to all 574 pediatricians on the AAP Washington State Chapter mailing list. From the original list of 792 physicians, we excluded all pediatric residents and all pediatricians known to deliver only specialty care. Approximately 94% of practicing pediatricians in Washington State are members of this chapter (T. Pendergrass, MD, MSPH, AAP Washington State Chapter, written communication, December 1997). Only those pediatricians who deliver preventive (well-child) care and offer immunizations completed the survey. However, all pediatricians were asked to return the survey to accurately assess the response rate. A second mailing was sent to all nonrespondents 4 weeks after the first.
The survey was divided into 3 parts. The first part primarily addressed whether the respondent was following the AAP/ACIP recommendations. The question contained structured choices ranging from recommending universal vaccination to actively discouraging the vaccine. Respondents were also offered the option selecting "other," and writing in their own policy. The second part consisted of a series of statements, representing both potential advantages and disadvantages of the varicella vaccine. After each statement, the pediatrician was asked to indicate his or her level of agreement using a 6-point Likert scale, with possible responses ranging from "completely agree" to "completely disagree." The final part of the questionnaire pertained to practice location and type, sources of vaccinerelated information, and physician demographics.
The reliability and validity of the questionnaire were tested by administering it to 29 pediatric residents at Children's Hospital and Medical Center, Seattle, Wash. Validity was assessed by examining (1) the correlation between the composite Likert scale score (summed scores divided by number of responses) and (2) the responses to both a structured general question about attitudes toward varicella and an open question asking for a single sentence summarizing that physician's opinion of the varicella vaccine recommendations (Spearman correlation coefficients, 0.783 and 0.874, respectively). 10 Reliability was assessed by examining the internal consistency between positive responses to positively worded questions and negative responses to negatively worded questions that addressed specific subtopics of vaccine necessity, cost-effectiveness, and potential risks (weighted : 0.618, 0.747, 0.767, respectively). Therefore, the composite Likert score appeared to represent a valid assessment of physician opinion about varicella, and the questionnaire displayed good internal reliability. For all analyses, physician varicella policy was reduced to a dichotomous variable: complete adherence to the AAP/ACIP guideline or some other policy. For univariate analysis, Likert-scale questions were reduced to a dichotomous variable: completely agree/agree vs any other response. Univariate analyses were performed using 2 tests to compare proportions for categorical variables and t tests to compare means for continuous variables. Tests were considered significant when the 2-sided P value was Ͻ.05.
For multivariate analysis, Likert responses were also reduced to dichotomous variables: completely agree/ agree vs any other response and completely disagree/ disagree vs any other response. For each Likert statement, the stronger of these 2 predictors was included in the initial multivariate model, which was performed using logistic regression (SPSS, Version 7, SPSS, Chicago, Ill). Only those variables found to be significantly associated with adherence to AAP varicella recommendations in univariate analysis were included in the initial multivariate model. Variables viewed as surrogate outcome measures (stocking varicella vaccine, agreement with AAP/ACIP policy, and belief that varicella vaccine should be given because it is recommended by AAP/ACIP) were excluded from multivariate analysis. Variables were retained in the final model if the 95% confidence interval (CI) for the odds ratio (OR) did not include 1.
Throughout the text and in Table 1 and Table 2 , we have used the word "agree" to include those responding "agree" and "completely agree," and the word "disagree" to include those responding "disagree" or "completely disagree."
The study was approved by the Institutional Review Board (IRB) of Children's Hospital and Medical Center.
State funds have been made available for the provision of free varicella vaccine to all children in Washington State. However, the state system for the purchase and To determine the rate of adherence to the new AAP/ ACIP varicella immunization recommendations, to understand sources of concern about the vaccine, and to evaluate factors that might influence adherence to these recommendations, we undertook a statewide survey of pediatricians in Washington State.
RESULTS
Of the initial mailing of 574 surveys, 6 were undeliverable. Surveys were returned by 434 of the remaining 568 pediatricians, for a response rate of 76%. After excluding responses from 89 physicians who indicated that they did not currently practice general pediatrics or offer preventive services, data from 345 surveys were analyzed.
Among the 345 pediatricians completing the survey, 146 (42%) reported recommending universal varicella vaccination. Of the remaining 199 (58%), 17% recommended the vaccine for susceptible adolescents but not for younger children; 14% did not routinely discuss the vaccine but believed they gave a balanced discussion if questioned; and 13% recommended the vaccine for adolescents and gave a balanced discussion for younger children. The remaining 14% of physicians had other policies.
There were few significant differences in demographic characteristics between those pediatricians who recommended universal varicella vaccination and those who did not. The mean age of all respondents was 45 years (age range, 28-74 years), and the mean number of years in practice was 15 (range, 1-45 years). Most of the pediatricians in both groups worked in either solo or group private practice (70%) in metropolitan areas (71%). The percentage of pediatricians working in neighborhood or community health centers was greater among those not following the varicella recommendations (7% vs 1%, PϽ.01).
Varicella vaccine was stocked and available in 88% of the primary offices of responding pediatricians. Pediatricians in practices that stocked the vaccine were significantly more likely to recommend universal vaccination than pediatricians in practices that did not stock the vaccine (46% vs 17%, PϽ.001).
Virtually every pediatrician (99%) responded that they used AAP policy statements for vaccine information. Eighty-five percent responded that they used the Red Book, 11 81% indicated that they used journal articles, 62% used continuing medical education for vaccine information, and 62% relied on colleagues for this information. These percentages did not differ significantly between those who did and did not recommend universal varicella vaccination. The most commonly identified primary source for vaccine-related information was policy statements by the AAP (52%). Those citing the AAP as their primary information source were more likely than other pediatricians to recommend universal vaccination (56% vs 31%, PϽ.001).
Overall, 80% of respondents had seen at least one serious complication resulting from varicella infection, including 55% who had seen pneumonia; 44%, encepha- litis; 38%, necrotizing fasciitis; and 19%, death. Sixtyone percent of pediatricians who had seen a death from varicella recommended universal immunization compared with 38% of those who had not (PϽ.01). Similarly, among those who reported experience with varicella encephalitis, 49% were following the recommendations, while among those who had not the rate was 35% (PϽ.01). There were no significant differences in following the recommendations among those who had experience with either pneumonia or necrotizing fasciitis secondary to varicella. While 44% of responding pediatricians agreed with the statement that the AAP/ACIP policy on universal varicella vaccination was warranted, only 22% agreed that pediatricians should administer the vaccine because it is recommended by the AAP/ACIP. More than half of pediatricians agreed that varicella vaccine would significantly reduce the incidence of serious varicella complications (66%), the discomfort of varicella (75%), and parental time lost from work (85%).
The proportion of pediatricians who agreed or completely agreed with statements on the questionnaire regarding attitudes about varicella vaccine are shown in Table 1 . With the exception of 4 statements, agreement with all positively worded statements and disagreement with all negatively worded statements were significantly associated with reported varicella immunization practices of respondents.
In multivariate analysis, 7 factors were significantly associated with following the AAP/ACIP varicella recommendations (Table 2) . Agreement with statements regarding the effectiveness of the vaccine in reducing rare but serious complications of the disease and in decreasing time lost at work by parents was associated with recommending universal immunization associated with adherence to the recommendation. Disagreement with statements concerning the lack of the need for varicella immunization because complications are rare, because it is not required for school entry, and because it is not medically cost-effective was also associated with universally recommending the vaccine. In addition, experience with varicella encephalitis was also associated with adherence to the recommendation. Conversely, those who were concerned that varicella vaccine might not provide lifelong immunity were less likely to report recommending universal vaccination.
COMMENT
The results of this study indicate that fewer than 50% of Washington State pediatricians report following the AAP/ ACIP guideline recommending universal varicella immunization. There were no differences in reported adherence to universal immunization recommendations based on sex, age, practice location, or number of years in practice. Instead, following the varicella immunization recommendations was positively associated with personal experience (having seen varicella encephalitis), concern over the potential seriousness of varicella complications, and a belief that varicella vaccine was a medically and societally cost-effective intervention. Conversely, those who were concerned that varicella immunity might not be lifelong were less likely to report universally recommending varicella vaccine for their patients.
While these results demonstrate that many pediatricians are concerned about the potential for adverse consequences of natural varicella infection, and that these concerns are strongly associated with their reported immunization practices, they also demonstrate that approximately half of those pediatricians not following the recommendations view varicella as a benign illness for which there is little impetus to give a vaccine. Coupled with the concern expressed by nearly 60% of those not following the recommendations that immunity may not be lifelong, it is clear that a large number of practicing pediatricians have important reservations about the necessity for and long-term utility of varicella vaccine.
Our results are in contrast to the experience with licensure of a vaccine to prevent Haemophilus influenzae type b infections. In one study, 6 to 8 months following the introduction of the H influenzae type b vaccine, 86% of pediatricians in New Mexico reported using the vaccine. 12 In the case of H influenzae type b, the undisputed severity of the disease appears to have led to a very rapid incorporation of a new vaccine into practice patterns.
Universal varicella immunization coverage appears a long way from reality, at least in Washington State. However, the failure of varicella vaccine to be immediately embraced by the pediatric community is not unique to this vaccine. Several months after the Centers for Disease Control and Prevention recommended that all children and adolescents be immunized against hepatitis B, a study in North Carolina demonstrated that only 32% of pediatricians felt that the policy was warranted in their practices. 13 However, a follow-up study 8 months later demonstrated that the belief that hepatitis B immunization was warranted had risen to 66%, although only 53% had adopted it into practice.
14 Over time, hepatitis B immunization rates have risen significantly; by 1996, it was estimated that 82% of children 19 to 35 months of age had received all 3 doses of hepatitis B vaccine. 15 In the case of the varicella vaccine, however, the consequences of failure to achieve universal coverage in a timely 
